Novavax begins clinical trial for combined influenza and COVID vaccine

US vaccine developer Novavax has announced the initiation of an early stage clinical trial investigating its combined influenza and COVID-19 vaccine.

The trial will enrol 640 healthy adults, between the ages of 50 and 70 years, who have either been previously infected with the coronavirus or given an authorised COVID-19 vaccine at least eight weeks prior to the study.

The study will be conducted at up to 12 study sites across Australia.

read more